

Xiaowei Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1413732/publications.pdf>

Version: 2024-02-01

29
papers

340
citations

758635

12
h-index

839053

18
g-index

36
all docs

36
docs citations

36
times ranked

574
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	0.8	52
2	CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13. <i>Angiogenesis</i> , 2017, 20, 505-518.	3.7	36
3	Flagellin-induced expression of CXCL10 mediates direct fungal killing and recruitment of NK cells to the cornea in response to <i>Candida albicans</i> infection. <i>European Journal of Immunology</i> , 2014, 44, 2667-2679.	1.6	26
4	The Effect of Topical Pranoprofen 0.1% on the Clinical Evaluation and Conjunctival HLA-DR Expression in Dry Eyes. <i>Cornea</i> , 2012, 31, 1235-1239.	0.9	25
5	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020, 11, 799-804.	0.8	24
6	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. <i>PLoS ONE</i> , 2020, 15, e0239939.	1.1	22
7	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	0.8	19
8	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. <i>Arthritis Research and Therapy</i> , 2019, 21, 44.	1.6	18
9	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1479-1488.	0.9	17
10	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 488-492.	0.8	17
11	Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients. <i>Rheumatology</i> , 2021, 60, 2635-2646.	0.9	16
12	RDH5 RETINOPATHY (FUNDUS ALBIPUNCTATUS) WITH PRESERVED ROD FUNCTION. <i>Retina</i> , 2015, 35, 582-589.	1.0	13
13	Bacterial Contaminants of Bandage Contact Lenses Used After Laser Subepithelial or Photorefractive Keratectomy. <i>Eye and Contact Lens</i> , 2012, 38, 227-230.	0.8	12
14	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	0.8	10
15	<i>Mycobacterium massiliense</i> Keratitis. <i>Optometry and Vision Science</i> , 2012, 89, E944-E947.	0.6	5
16	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020, 11, 829-834.	0.8	5
17	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020, 11, 1099-1104.	0.8	5
18	Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort. <i>Frontiers in Medicine</i> , 2021, 8, 784520.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Effects of excimer laser phototherapeutic keratectomy in limbal-conjunctival autograft transplantation for recurrent pterygium: a retrospective case control study. BMC Ophthalmology, 2019, 19, 238.	0.6	3
20	Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. BMC Ophthalmology, 2021, 21, 447.	0.6	3
21	Management of immune checkpoint inhibitor-related rheumatic adverse events. Thoracic Cancer, 2020, 11, 198-202.	0.8	2
22	Impact of Unilateral Orbital Radiotherapy on the Structure and Function of Bilateral Human Meibomian Gland. Journal of Ophthalmology, 2018, 2018, 1-7.	0.6	0
23	Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobulin G4-related disease. Chinese Medical Journal, 2021, Publish Ahead of Print, .	0.9	0
24	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. , 2020, 15, e0239939.		0
25	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. , 2020, 15, e0239939.		0
26	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. , 2020, 15, e0239939.		0
27	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. , 2020, 15, e0239939.		0
28	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. , 2020, 15, e0239939.		0
29	Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. , 2020, 15, e0239939.		0